Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Subst Use Misuse ; 59(9): 1352-1356, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38688898

RESUMEN

PURPOSE: The most commonly used intervention for opioid overdoses is naloxone. With naloxone soon to be sold over-the-counter in the United States, the goal of this paper is to categorize frequently asked questions (FAQs) and answers about naloxone using internet sources in a cross-sectional fashion. METHODS: Terms "narcan" and "naloxone" were searched on a clean Google Chrome browser using the "People also asked" tab to find FAQs and their answer sources. We classified questions and sources and assessed each website's quality and credibility grading with JAMA benchmark criteria. The Kruskal-Wallis H test was used to determine variance of mean JAMA score by source type and Post-Hoc Dunn's test with Bonferroni corrected alpha of 0.005 used to compare source types. RESULTS: Of the 305 unique questions, 202 (66.2%) were classified as facts, 78 (25.6%) were policy, and 25 (8.2%) were value. Of the 144 unique answer sources, the two most common included 55 (38.2%) which were government entities and 47 (32.6%) which were commercial entities. Ninety-two (of 144, 63.9%) sources met three or more JAMA benchmark criteria. Statistical analysis showed a significant difference between the JAMA benchmark scores by source type H(4) = 12.75, p = 0.0126 and between the mean rank of academic and government sources (p = 0.0036). CONCLUSION: We identified FAQs and their citations about naloxone, highlighting potential lack of understanding and knowledge of this important intervention. We recommend updating websites to accurately reflect current and useful information for those that may require naloxone.


Asunto(s)
Internet , Naloxona , Antagonistas de Narcóticos , Naloxona/uso terapéutico , Humanos , Antagonistas de Narcóticos/uso terapéutico , Estudios Transversales , Estados Unidos , Conocimientos, Actitudes y Práctica en Salud
2.
J Emerg Med ; 59(5): 699-704, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33011038

RESUMEN

BACKGROUND: A small subset of pediatric patients develop a rare syndrome associated with Coronavirus Disease 2019 (COVID-19) infection called multisystem inflammatory syndrome in children (MIS-C). This syndrome shares characteristics with Kawasaki disease. CASE REPORT: A 15-year-old girl presented to our Emergency Department (ED) with fevers and malaise. She was diagnosed on her initial visit with an acute viral syndrome and discharged with a COVID polymerase chain reaction test pending, which was subsequently negative. She returned 3 days later with persistent fever, conjunctivitis, and a symmetric targetoid rash over her palms. She had no adenopathy, but her erythrocyte sedimentation rate and C-reactive protein were both significantly elevated at 90 mm/h and 19.61 mg/dL, respectively. The patient was then transferred to the regional children's hospital due to a clinical suspicion for MIS-C, and subsequent COVID-19 immunoglobulin G testing was positive. She had been empirically started on intravenous immunoglobulin in addition to 81 mg aspirin daily. Initial echocardiograms showed mild dilatation of the left main coronary artery, and on repeat echocardiogram, a right coronary artery aneurysm was also identified. Oral prednisone therapy (5 mg) was initiated and the patient was discharged on a continued prednisone taper. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: We present a case of a 15-year-old girl who presented to the ED with MIS-C who developed coronary aneurysms despite early therapy, to increase awareness among emergency physicians of this emerging condition.


Asunto(s)
COVID-19/diagnóstico , Aneurisma Coronario/etiología , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Adolescente , Sedimentación Sanguínea , Proteína C-Reactiva/análisis , Servicio de Urgencia en Hospital , Femenino , Ferritinas/sangre , Glucocorticoides/uso terapéutico , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Interleucina-6/sangre , Prednisona/uso terapéutico , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Tratamiento Farmacológico de COVID-19
4.
J Am Mosq Control Assoc ; 24(4): 528-33, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19181060

RESUMEN

The Mosquito Sentinel 360 (MS) trap was evaluated in back yards of 6 residences in and near Gainesville, FL. Carbon dioxide and blue-light-emitting diode-modified Centers for Disease Control and Prevention (CDC) traps were utilized as a human substitute host to provide a measure of the effectiveness of the MS trap in reducing mosquito presence at the back door area of the houses. At 5 of the 6 residences, a MS trap was operated with or without carbon dioxide, Lurex3 + octenol, or an experimental attractant. All MS traps were operated in tandem with a CDC trap, with the 6th site occupied only by a CDC trap. Over 67,000 mosquitoes from 19 species were recovered over the 12 trial days. Of these species, Anopheles crucians, An. quadrimaculatus, Coquillettidia perturbans, Culex erraticus, and Mansonia titillans were the predominant, nuisance, and medically important species captured and accounted for >92% of specimens recovered. Overall, attractant-modified MS traps captured more mosquitoes than the paired CDC trap. Carbon dioxide was found to greatly increase the capture of mosquitoes; however, the Lurex3 + octenol combination was significant with Cq. perturbans. All attractant-modified MS traps captured more Cx. erraticus and Ma. titillans than did the CDC, CO2-baited host mimic traps. The use of the MS 360 trap will undoubtedly require the addition of baits and perhaps the inclusion of a host masking or repellent approach to ensure protection from nuisance mosquitoes in residential environments.


Asunto(s)
Culicidae , Control de Mosquitos/instrumentación , Animales , Dióxido de Carbono , Florida , Luz , Control de Mosquitos/métodos , Octanoles
5.
Biochem Pharmacol ; 73(11): 1818-28, 2007 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-17343833

RESUMEN

Chronic opioid treatment leads to agonist-specific effects at the mu opioid receptor. The molecular mechanisms resulting from chronic opioid exposure include desensitization, internalization and down-regulation of membrane-bound mu opioid receptors (MOP). The purpose of this study was to compare the cellular regulation of guinea pig, human and rat MOP expressed in Chinese hamster ovary (CHO) cells, following exposure to two clinically important opioids, morphine and methadone. MOP expressing CHO cells were treated in culture with methadone or morphine for up to 48 h. Radioligand diprenorphine and [D-AIa(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO)-stimulated GTP gamma S binding assays were carried out using paired control and opioid-exposed CHO cells. Methadone induced downregulation of the mu opioid receptor, while morphine induced desensitization of the receptor for all three species. Furthermore, morphine predominantly decreased the potency of DAMGO to stimulate GTP gamma S binding, whereas methadone primarily reduced its efficacy. Changes in DAMGO potency and efficacy differed among species and depended on the opioid used to treat the cells. Our results showed similarities between guinea pig and human MOP for morphine-induced desensitization, but identified differences between the two for methadone-induced desensitization. In contrast, human and rat MOP differed in response to morphine treatment, but were not distinct in their response to methadone treatment. The guinea pig is an excellent and established animal model to study opioid effects, but its molecular opioid pharmacology has not been investigated thus far. These results can assist in understanding species differences in the effects of opioid ligands activating the mu opioid receptor.


Asunto(s)
Analgésicos Opioides/farmacología , Unión Competitiva/efectos de los fármacos , Morfina/farmacología , Receptores Opioides mu/metabolismo , Animales , Células CHO , Cricetinae , Cricetulus , Femenino , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Cobayas , Humanos , Ratas , Receptores Opioides mu/efectos de los fármacos , Especificidad de la Especie , Transfección
6.
Pediatr Pulmonol ; 42(12): 1134-43, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17968993

RESUMEN

Respiratory depression, the most serious side-effect of opioid treatment, is well documented for morphine, the most commonly used opioid in neonatal care. Less is known about methadone, a clinically relevant opioid analgesic, especially during neonatal development. This study was undertaken to determine the neonatal respiratory effects of methadone. We hypothesize that methadone is equipotent to morphine, compared to our previous morphine results in the same animal model, but has a much longer duration of action, due to its longer elimination half-life. Neonatal guinea pigs (3-14 days old) randomly received a single subcutaneous dose of methadone or saline. Using a non-invasive plethysmographic method, we measured ventilatory and metabolic parameters before injection and at intervals for 32 hr after injection while pups breathed "room air" or 5% CO(2) gas mixtures. Methadone-induced depression of ventilation was most evident during 5% CO(2) challenge. The onset of drug effects was within 15 min for all ages and doses, but the duration of action decreased with age. While the depth of methadone-induced respiratory depression did not depend on pup age, the control of breathing was different in 3-day-old pups, where inspiratory time increased fourfold; twice that of older pups. We conclude that methadone induces a naloxone reversible respiratory depression in guinea pig neonates and, in the very young, causes an abnormal breathing pattern due to changes in respiratory timing. Methadone is more potent than morphine with respect to neonatal respiratory depression, but surprisingly, the duration of methadone action was not longer than morphine.


Asunto(s)
Metadona/toxicidad , Narcóticos/toxicidad , Insuficiencia Respiratoria/inducido químicamente , Animales , Animales Recién Nacidos , Análisis de los Gases de la Sangre/métodos , Pruebas Respiratorias/métodos , Dióxido de Carbono/análisis , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Flujo Espiratorio Forzado/efectos de los fármacos , Cobayas , Inyecciones Subcutáneas , Volumen de Reserva Inspiratoria/efectos de los fármacos , Metadona/administración & dosificación , Naloxona/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Narcóticos/administración & dosificación , Consumo de Oxígeno/efectos de los fármacos , Pletismografía , Pronóstico , Insuficiencia Respiratoria/tratamiento farmacológico , Insuficiencia Respiratoria/fisiopatología
7.
J Allergy Clin Immunol ; 119(6): 1415-22, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17418379

RESUMEN

BACKGROUND: Eosinophils cluster along airway nerves in patients with asthma and release eosinophil major basic protein, an antagonist of inhibitory M2 muscarinic receptors on nerves. Blocking M2 function increases bronchoconstriction, leading to airway hyperreactivity. Intercellular adhesion molecule-1 (ICAM-1) mediates eosinophil adhesion to nerves. OBJECTIVE: We investigated mechanisms of ICAM-1 expression by parasympathetic nerves. METHODS: ICAM-1 expression was examined by immunocytochemistry of lung sections from ovalbumin-sensitized and challenged guinea pigs. ICAM-1 was measured in parasympathetic nerves isolated from subjects and guinea pigs and in human neuroblastoma cells by real-time RT-PCR, immunocytochemistry, and Western blot. RESULTS: ICAM-1 was not detected in control airway parasympatheric nerves in vivo or in cultured cells. ICAM-1 was expressed throughout antigen-challenged guinea pig lung tissue and was selectively decreased by dexamethasone only in nerves. ICAM-1 was induced in human and guinea pig parasympathetic nerves by TNF-alpha and IFN-gamma and was inhibited by dexamethasone and by an inhibitor of nuclear factor-kappaB (NF-kappaB). In neuroblastoma cell lines TNF-alpha and IFN-gamma-induced ICAM-1 was blocked by an inhibitor of NF-kappaB but not by inhibitors of mitogen-activated protein kinases. Dexamethasone did not inhibit ICAM-1 expression in neuroblastoma cells. CONCLUSIONS: ICAM-1 induced in nerves by antigen challenge and proinflammatory cytokines is sensitive to dexamethasone. ICAM-1 expression is also sensitive to inhibitors of NF-kappaB. Neuroblastoma cells mimic many, but not all, characteristics of ICAM-1 expression in parasympathetic nerves. CLINICAL IMPLICATIONS: Dexamethasone and NF-kappaB inhibitors could prevent eosinophils from adhering to nerves by blocking ICAM-1 expression on parasympathetic nerves, thus protecting inhibitory M2 muscarinic receptors and making this pathway a potential target for asthma treatment.


Asunto(s)
Regulación de la Expresión Génica/fisiología , Molécula 1 de Adhesión Intercelular/biosíntesis , Molécula 1 de Adhesión Intercelular/genética , Pulmón/inervación , Sistema Nervioso Parasimpático/metabolismo , Animales , Línea Celular Tumoral , Células Cultivadas , Cobayas , Humanos , Mediadores de Inflamación/farmacología , Molécula 1 de Adhesión Intercelular/metabolismo , Interferón gamma/farmacología , Pulmón/citología , Pulmón/metabolismo , Neuronas/inmunología , Neuronas/metabolismo , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Sistema Nervioso Parasimpático/citología , Factor de Necrosis Tumoral alfa/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA